Ensuring the Highest Quality and Safety of AlliaPharm Europe Medicines.

At AlliaPharm Europe, ensuring the quality and safety of our medicines is one of our top priorities. To achieve this, we have implemented a robust pharmacovigilance system that complies with international standards and regulatory requirements in the countries where we operate. This system enables us to monitor, evaluate, and manage the safety and efficacy of our medicines at both national and international levels.

What is Pharmacovigilance?

Pharmacovigilance involves identifying, collecting, evaluating, and preventing adverse reactions, unexpected events, and any other safety concerns associated with the use of medicines.
Adverse reactions refer to any unintended and harmful effects caused by a medicine, whether triggered by active ingredients, manufacturing issues. While the highest-quality medicines reduce risks, adverse events may still occur due to the pharmacological properties of the components or individual responses to treatment. Pharmacovigilance addresses these challenges by ensuring continuous safety monitoring throughout a medicine's lifecycle—from development to post-market use.

Why Pharmacovigilance Matters?

Pharmacovigilance allows us to analyze real-world data, adjust the benefit-risk profile of medicines, and minimize potential adverse effects. By implementing risk minimization measures, we ensure patients receive the most effective and safe treatments possible.

Your Role in Ensuring Safety.

We value all information regarding the safety of AlliaPharm Europe products. If you become aware of any of the following:

• Adverse reactions;
• Lack of therapeutic effect;
• Overdose, misuse, off-label use, medical errors, or occupational exposure;
• Transmission of infection through a medicine;
• Use during pregnancy or breastfeeding;
• Effects on an embryo or fetus (via maternal use or paternal transmission);
• Unexpected therapeutic effects;
• Drug interactions;
• Suspected adverse reactions due to quality defects or counterfeit products.

We strongly encourage you to report any adverse events by completing the Adverse Event Reporting Form available on our website. You may also inform us about an adverse reaction by contacting us by phone or email using the contact details provided below.

What Information to Include in Your Report:

Details about the reporter: Name, phone number, country, email, and qualification (e.g., healthcare professional or non-medical individual).
Information about the patient: Initials, age, gender, etc.
Information about the medicine: Brand name, dosage, treatment period, batch number, etc.
Description of the issue: Adverse reaction or other safety-related concerns.
Even if all the information is not available, we encourage you to report any problem related to AlliaPharm Europe medicines.

Contact Information for Reporting Issues:

Ukraine: Email: pv@alliapharm.com
Hungary: Email: pv@alliapharm.com Phone: +36 30 746 2006
Your reports help us ensure the continued safety and efficacy of our products, supporting better health outcomes for all.